Study of the Fimasartan effects on cardiovascular events and metabolic syndrome in patients with hypertensio

Not Applicable

Completed

• Conditions: Diseases of the circulatory system

• Registration Number: KCT0000529
• Lead Sponsor: Cheil General Hospital & Women's healthcare center

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 11 March 2019

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 20000

Inclusion Criteria

1.Patients with hypertension who are 20 years old and higher and need angiotensin ? receptor blockers(ARBs), Fimasartan(Kanarb)
2.Patients who agreed to this study and handed out written consent forms
3.Patients who visited after fasting

Exclusion Criteria

1. Patients who are currently taking Kanarb

Study & Design

• Study Type: Observational Study
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
the frequency and incidence of major adverse cardiovascular event(MACE) in the treated kanarb during average 3 years of follow-up visits using a cohort study with office hypertension

Secondary Outcome Measures

Name	Time	Method
Changes in degree of metabolic risk after 3 months of follow-up observation.;A incidence of metabolic syndrome and diabetes after 1-year follow-up ;Effect of blood pressure changes and side effects according to presence or absence of metabolic syndrome;Difference of clinic and home blood pressure after Kanarb treatment;changes of incidence of white coat and masked hypertension after Kanarb treatment;Changes of blood pressure variability after Kanarb treatment